ロード中...
A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis
BACKGROUND: Treatment with nab-paclitaxel with gemcitabine demonstrates a survival advantage when compared with single-agent gemcitabine. However, the combination is associated with significant toxicities, leading to a high rate of drug discontinuation. We implemented a modified regimen of gemcitabi...
保存先:
| 出版年: | Ther Adv Med Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
SAGE Publications
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5298402/ https://ncbi.nlm.nih.gov/pubmed/28203300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834016676011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|